Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy

Antibody–Drug Conjugates for Cancer Treatment

(2018) John M. Lambert et al.   Annual Review of Medicine

OUP accepted manuscript

(2018)   BIOINFORMATICS

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

(2018) Guangmin Li et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Phosphatidylserine with Calcium-Dependent Protein–Drug Conjugates for the Treatment of Cancer

(2017) Ran Li et al.   MOLECULAR CANCER THERAPEUTICS

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

(2016) John Y. Li et al.   CANCER CELL

New developments for antibody-drug conjugate-based therapeutic approaches

(2016) Bart ECG de Goeij et al.   CURRENT OPINION IN IMMUNOLOGY

Downregulation of the neonatal Fc receptor expression in non-small cell lung cancer tissue is associated with a poor prognosis

(2016) Emilie Dalloneau et al.   Oncotarget

Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption

(2016) Rafal Swiercz et al.   Oncotarget

Antibody Drug Conjugates: Nonclinical Safety Considerations

(2015) Mary Jane Masson Hinrichs et al.   AAPS Journal

FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin

(2015) Michal Pyzik et al.   JOURNAL OF IMMUNOLOGY

Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index

(2015) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells

(2014) Sripad Ram et al.   mAbs

The effect of pH dependence of antibody-antigen interactions on subcellular trafficking dynamics

(2013) Siva Charan Devanaboyina et al.   mAbs

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9

(2012) Javier Chaparro-Riggers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKaPredictions

(2011) Mats H. M. Olsson et al.   Journal of Chemical Theory and Computation

A Software Framework for the Analysis of Complex Microscopy Image Data

(2010) Jerry Chao et al.   IEEE TRANSACTIONS ON INFORMATION TECHNOLOGY IN BIOMEDICINE

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

(2010) Tomoyuki Igawa et al.   NATURE BIOTECHNOLOGY